Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mGlu5 NAM
- Development stage
- Preclinical
- Lead developer
- Warren Center for Neuroscience Drug Discovery
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal, Intravenous, Subcutaneous
01
Overview
mGlu5 NAM refers to a preclinical-stage small molecule program developed by the Warren Center for Neuroscience Drug Discovery (WCNDD) for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and Lewy Body Dementia (LBD). The program focuses on the negative allosteric modulation of the metabotropic glutamate receptor 5 (mGlu5). By binding to an allosteric site rather than the orthosteric glutamate binding site, these compounds reduce the receptor's signaling activity in response to glutamate. This mechanism is hypothesized to provide neuroprotective effects by mitigating glutamate excitotoxicity and reducing the aggregation of pathological proteins such as amyloid-beta and alpha-synuclein. The program is currently in the hit-to-lead and lead optimization stages of development.
- Other names
- mGlu5 NAMmGlu-5 NAMmGlu 5 NAMmGluR5 NAMmGluR-5 NAMmGluR 5 NAMmetabotropic glutamate receptor 5 negative allosteric modulator
02
Targets
GRM5 (Metabotropic glutamate receptor 5)
Beyond the preview
Go deeper on mGlu5 NAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mGlu5 NAM.